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Abstract
Hepatitis C virus (HCV) infects over 150 million people 
worldwide. In most cases, HCV infection becomes 
chronic causing liver disease ranging from fibrosis 
to cirrhosis and hepatocellular carcinoma. Viral 
persistence and pathogenesis are due to the ability of 
HCV to deregulate specific host processes, mainly lipid 
metabolism and innate immunity. In particular, HCV 
exploits the lipoprotein machineries for almost all steps 
of its life cycle. The aim of this review is to summarize 
current knowledge concerning the interplay between 
HCV and lipoprotein metabolism. We discuss the 
role played by members of lipoproteins in HCV entry, 
replication and virion production. 
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Core tip: The aim of the review is to summarize current 
knowledge concerning the interplay between hepatitis 
C virus (HCV) and lipoprotein metabolism. In particular, 
the manuscript discusses the role played by members 
of lipoproteins family in all steps of HCV life cycle.
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INTRODUCTION
Hepatitis C virus (HCV) infection is one of the main 
causes of chronic liver disease worldwide. It has been 
estimated that 130-170 million people are chronically 
infected with HCV[1-3] with a prevalence, in selected 
countries, ranging from 0.4% to 12.3%[4].
Acute infection is spontaneously cleared only in 
15%-30% of individuals and the majority of patients 
develop chronic infection. HCV infection is generally a 
slowly progressive disease characterized by different liver 
damages that can progress to life-threatening diseases, 
such as cirrhosis and hepatocellular carcinoma[5,6]. 
The recent advent of highly potent direct-acting 
antiviral drugs (DAAs), employed in interferon-
containing and interferon-free combinations, has 
led to virus elimination in more than 90% of treated 
patients[7]. However, it is yet unclear whether, and 
how, the virus-induced liver damages are reversible; 
therefore, it is important to fully elucidate the me-
chanism of HCV-induced pathogenesis.
HCV does not cause a direct cytopathic effect on 
host cells and most of the related liver dysfunctions 
are likely due to the virus-mediated alteration of host 
processes such as immune responses and several 
metabolic pathways[8-10]. In particular, HCV interferes 
with the host lipid metabolism and cholesterol 
homeostasis. Several lipids abnormalities have been 
associated to HCV chronic infection, such as liver 
steatosis, particularly evident in patients infected with 
the genotype 3 of the virus, hypobetalipoproteinemia 
and hypocholesterolemia[11].
The relationship existing between the virus and the 
lipid metabolism is very intimate, every step of the 
viral life cycle relies at least on one member involved 
in lipid pathways[12,13]. 
HCV is an enveloped positive-strand RNA virus, a 
member of the genus Hepacivirus within the family of 
Flaviviridae. HCV enters the cell by receptor-mediated 
endocytosis involving multiple cell surface molecules 
(as recently reviewed by Ding and coauthors[14]). 
After pH-dependent fusion and uncoating, the 9.6 
kb single-stranded RNA genome is translated at the 
rough endoplasmic reticulum (ER). The resulting 
polyprotein precursor is processed by cellular and viral 
proteases into ten mature proteins; core and envelope 
glycoproteins E1 and E2 are the main constituents of 
the virus particle, p7 and nonstructural protein (NS) 2 
participate in virus assembly, while NS3, NS4A, NS4B, 
NS5A, and NS5B are sufficient for viral RNA replication 
and are involved in virus assembly[15]. Replication 
takes place in ER-derived membrane spherules called 
membranous web, which formation and architecture 
remain to be fully elucidated. Progeny RNA is then 
packaged into virus particles that exit the cell via the 
secretory pathway[16].
Lipoproteins are responsible for lipids packaging 
and transport through the bloodstream and for their 
delivery to target tissues. The transported lipids, 
which are the core of the lipoproteins, are cholesteryl 
esters (CE) and triglycerides (TG), derived either 
from the diet or from liver neo-synthesis. They are 
enveloped by a layer of phospholipids, free cholesterol 
and proteins (mainly apolipoproteins), which control 
lipoproteins assembly, transport and metabolism by 
mediating interactions with receptors, enzymes and 
lipid transport proteins[17,18]. Lipoproteins vary in the 
content of lipids and proteins. Their classification and 
isolation procedures are commonly based on their 
density, which reflect their different content of CE, 
TG, free cholesterol and apolipoproteins. The main 
lipoproteins particles generated by the liver are the 
very low-density lipoproteins (VLDL), intermediate-
density lipoproteins (IDL), low-density lipoproteins 
(LDL), in which apolipoprotein(apo)B-100 (apoB) 
is the main structural component, and high-density 
lipoproteins (HDL), where apoA-I is the main structural 
component[17,18].
In the endogenous transport pathway, the liver 
releases TG and CE in the circulation mainly through 
the generation of VLDL particles[19]. Mobilized lipid 
storage pool in the liver, as well as de novo synthesis 
of fatty acids and phospholipids, contribute to hepatic 
VLDL synthesis. Lipoprotein lipase (LPL) hydrolyses the 
TG present in the core of circulating VLDL, releasing 
free-fatty acids (FFA) to the target tissues. A large 
proportion of the resulting particles (IDL) is efficiently 
removed from plasma by the hepatocytes through the 
LDL receptor (LDLR). The remaining part is converted 
to LDL by a reaction catalyzed by hepatic lipase, which 
further reduces the amount of TG. Once formed, 
CE-rich LDL delivers cholesterol to peripheral tissues 
where are taken up by the LDLR and internalized via 
a clathrin-dependent pathway. Following endocytosis, 
LDL are degraded into lysosomes and free cholesterol 
is released and either accumulated within the cells or 
incorporated into new lipoproteins. 
In the reverse transport system, HDL carry the 
excess of cholesterol from extrahepatic cells to the 
liver. HDL biosynthesis and maturation are complex 
multistep processes that involve the secretion of 
proteins-rich and lipid-poor particles (nascent HDL) 
and a massive extracellular lipid acquisition of mainly 
phospholipids and cholesterol. The major lipid 
components of HDL are CE and phospholipids, while 
apoA-I and apoA-Ⅱ are the main apolipoproteins 
required for normal HDL biosynthesis[17,18].
Several steps of HCV life cycle are strictly linked to 
host lipoprotein metabolism, the aim of this review is to 
describe this close relationship (summarized in Table 1).
HCV ENTRY AND LIPOPROTEINS
Viral particles purified from infected patients sera 
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revealed that HCV has a spherical morphology of 
different sizes (range 40-70 nm diameter), with an 
enveloped membrane displaying the two surface viral 
glycoproteins E1 and E2[20,21]. HCV exists as a mixture 
of infectious and noninfectious particles, both in vivo 
and in vitro, and, very interestingly, virions found with 
a very low buoyant density (range 1.10-1.14 g/mL) 
displayed the highest infectivity[22-26].
The high buoyant density is mainly due to the 
association with apoB-containing lipoproteins (VLDL/
LDL) to form the so-called lipoviral particles (LVP). 
Different lipoproteins components, such as cholesterol, 
TG, apoB, apoE, apoA-I and apoCs, have been found in 
the LVP of HCV infected patients[27,28]. In vitro produced 
HCV particles have confirmed these associations[26,29,30]. 
HCV LVP enter into the cells via a multi-step endo-
cytosis that requires a growing number of receptors, 
co-receptors and host factors, which probably are 
responsible for the hepatotropism of the virus. The 
long list of these host proteins includes two binding 
factors glycosaminoglycans (GAGs) and low-density 
lipoprotein receptor (LDLR), four receptors CD81, 
scavenger receptor class B type 1 (SR-BI), claudin-1 
(CLDN1), occludin (OCLN), and several co-receptors 
epidermal growth factor receptor (EGFR), ephrin 
receptor A2 (EphA2), the cholesterol transporter 
Niemann-Pick C1-like 1 (NPC1L1), transferrin receptor 
1 (TfR1) and the cell-death-inducing DFFA-like effector 
b (CIDEB). For an exhaustive description of all known 
HCV receptors and their involvement in HCV cell entry, 
we refer the reader to recent reviews and references 
therein[14,31]. Here we will focus on molecules involved 
in lipoprotein metabolism.
HCV entry into the cells is a process that requires 
spatial and temporal control of these cellular cofactors. 
The putative mechanism consists of three main steps 
(1) viral attachment to the hepatocyte; (2) receptor-
mediated endocytosis; and (3) endosomal fusion. 
Members of the lipoprotein metabolism seem to be 
involved in all these steps.
Attachment of the virus to the host cell is firstly 
obtained by the interactions with GAGs and LDLR 
present on the surface of the cells, which are known 
to mediate lipoprotein metabolism[32]. It has been 
demonstrated that HCV binds to the GAGs present 
on heparan sulfate (HS) proteoglycans (HSPGs) and 
syndecan 1 and syndecan 4 have been reported to 
be involved in this process[33,34]. The minimum HS 
oligosaccharide length required for HCV infection 
is a decasaccharide with the N- and 6-O-sulfation. 
Very interestingly, it has been reported that apoE is 
responsible for this process, while viral glycoproteins, 
although capable of binding to GAGs, are not 
involved[35,36]. 
The LDLR, which transports the cholesterol-rich 
LDL intracellularly via clathrin-mediated endocytosis[37], 
is involved in this first step of HCV entry. However, its 
exact role in HCV infection still remains controversial; 
it is not clear whether it acts as a HCV receptor or 
as a facilitator of initial attachment to hepatocyte 
surface or for other steps of the virus life cycle, such 
as viral replication[38-44]. It is worth to note that the 
internalization of infectious particles and lipoproteins 
mediated by LDLR displays different kinetics, thus 
suggesting distinct uptake steps/pathways for HCV 
and lipoproteins[42].
The capture of viral particles is mediated by other 
members of the lipoprotein metabolism. In fact, after 
the initial interaction with GAGs and LDLR, HCV utilizes 
SR-BI, a major receptor of high-density lipoproteins 
(HDL) that can bind also apoB-containing lipoproteins 
(VLDL/LDL) and oxidized forms of LDL[45,46]. SR-BI is a 
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Table 1  Components of lipoprotein metabolism involved in hepatitis C virus life cycle
Name Lipoprotein association Main function HCV life cycle step Function Ref.
GAGs Lipoproteins adsorption Entry LVP adsorption [33-36,40]
LDLR apoE- and apoB-containing lipoproteins 
receptor
Entry LVP binding [37-44]
RNA replication Cellular distribution of lipids [42]
ApoB VLDL and LDL Structural protein of VLDL/LDL Virion production ? [102-105,110]
ApoE VLDL, LDL and HDL Ligand of LDL receptor Entry GAGs/LDLR binding [35,36,51]
Virion production ? [106-111]
ApoA-I HDL >> VLDL Structural protein of HDL RNA replication ? [82,83]
Virion production ? [82,110,111]
ApoH VLDL >> HDL Cholesterol efflux RNA replication ? [85]
ApoA-Ⅱ HDL >> VLDL Structural protein of HDL Virion production ? [110,111]
ApoC-I VLDL, LDL, HDL Inhibitor of CETP activity Entry Viral and cellular membranes 
fusion
[58,59]
Virion production ? [110,111]
ApoC-Ⅱ VLDL, LDL, HDL Activator of LPL Virion production ? [110,111]
ApoC-Ⅲ VLDL, LDL, HDL Inhibitor of LPL and HL Virion production ? [110,111]
ACSL3 Phosphatidylcholine synthesis for apoB Virion production ? [105]
GAGs: Glycosaminoglycans; LDL: Low-density lipoproteins; LDLR: LDL receptor; ApoB: Apolipoprotein B-100; VLDL: Very low-density lipoproteins; 
HDL: High-density lipoproteins; LVP: Lipoviral particles; LPL: Lipoprotein lipase; HL: Hepatic lipase; CETP: Cholesteryl ester transfer protein; ACSL3: 
Cyl-coenzyme A synthetase 3.
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uptake, HCV co-receptor complexes are trafficked 
to RAB5A containing endosomes for HCV fusion[57]. 
Interestingly, receptor-specific antibodies and HCV 
particles increased CD81 and CLDN1 endocytosis, thus 
supporting a model wherein HCV stimulates receptor 
trafficking to promote viral particle internalization.
After viral internalization, the interaction between E2 
and CD81 induces a yet unknown fusion mechanism 
between the viral glycoproteins and the endosomal 
membrane in a low-pH environment. Interestingly, 
this process is favoured by apoC-I, an exchangeable 
apolipoprotein that predominantly resides in HDL[58,59]. 
ApoC-I specifically enhances the infectivity of HCVcc 
and HCVpp as well as of HCV isolated from viremic 
chimpanzees. ApoC-I increases the infectivity via 
a direct interaction with the HCV glycoproteins. 
Interestingly, the hypervariable region 1 (HVR1), 
located at the N-terminus of the HCV E2 glycoprotein, 
is the essential viral component for the apoC-I-
mediated activity[58]. ApoC-I activity does not rely on 
SR-BI or CD81, thus not influencing the binding or 
the internalization steps of HCV entry. ApoC-I instead 
enhances the pH-dependent fusion rates between viral 
and target membranes, as measured by a HCVpp/
liposome fusion assay[58].
Following fusion, HCV genomic RNA is released into 
the cytosol, where it is directly translated to produce 
viral proteins and initiate viral replication.
HCV REPLICATION AND LIPOPROTEINS
HCV RNA replication is a multi-step process regulated 
by several viral and cellular proteins[60]. It is well 
established that the minimal viral proteins necessary 
and sufficient for viral replication are NS3-4A, NS4B, 
NS5A and NS5B, together with 5’ and 3’ untranslated 
regions[15]. HCV replication occurs within a dense 
cluster of rearranged intracellular membranes referred 
to as membranous web. It is composed by double-
membrane vesicle structures, most likely derived 
from the ER[61]. This membranous matrix is the center 
of HCV replication. In fact, it contains all the non-
structural viral proteins necessary for replication 
as well as the newly synthesized viral RNA[62]. It is 
worth to note that, although the membranous web 
is induced by all HCV replicase factors (NS3-5B)[61], 
the sole expression of NS4B and NS5A induces very 
similar membrane alterations[63,64]. HCV, through 
NS5A, hijacked the isomerase activity of cyclophilin 
A (CypA)[65,66] and the membrane-deforming ability 
of proline-serine-threonine phosphatase interacting 
protein 2 (PSTPIP2)[67] for remodeling intracellular 
membranes and, thus, enhancing HCV replication.
The replication step of HCV life cycle is highly 
linked to the host lipid metabolism processes. RNA 
replication occurs in membranes rich in cholesterol 
and sphingolipids, two lipids not abundant in the ER 
membrane[68]. Since HCV hijacks host lipid metabolism 
at different levels, it is likely that these lipids are 
glycoprotein with two N- and C-terminal cytoplasmic 
domains separated by a large extracellular domain, 
which is involved in lipoprotein metabolism, mediating 
the uptake and the intracellular delivery of the 
cholesterol esters (CE). Interestingly, the SR-BI-
mediated intracellular lipid transportation is different 
from that of the LDLR. In fact, it binds lipoproteins 
on the cell surface and delivers CE intracellularly 
without internalization of the intact lipoprotein particle 
(as reviewed by Shen and coauthors[47]). This could 
partially explained the aforementioned distinct 
internalization pathways described for HCV and 
lipoproteins[42].
The interaction between HCV and SR-BI is thought 
to mediate the dissociation of lipoproteins from LVP, 
likely through the SR-BI-mediated cholesterol transfer 
activity, and to induce conformational changes in 
the E2 glycoprotein, exposing its CD81 interaction 
domains[48,49]. Interestingly, it has been reported that 
HDL increases HCV entry into the cells by accelerating 
their endocytosis through SR-BI activation, with the 
consequence of decreasing the neutralizing effect of 
the anti-HCV antibodies[50]. On the other hand, apoB-
containing lipoproteins competed and effectively 
inhibited the interaction between HCV and hepatocytes 
and, as reported for LDLR, the binding to SR-BI is not 
mediated by E2 but mainly, although not exclusively, 
by apoE[51].
Together, these studies suggest that the first step 
of HCV entry is regulated by the complex interactions 
occurring between lipoproteins components, lipo-
proteins receptors (i.e., GAGs, LDLR and SR-BI) and 
HCV envelope glycoproteins.
After the attachment to the cells, HCV binds 
its receptors, the tetraspanin CD81 and the tight 
junction proteins CLDN1 and OCLN, leading to 
cellular internalization of the virus through a clathrin-
dependent endocytosis process. After the binding 
to HCV, CD81 moves toward the tight junctions and 
interacts with CLDN1. This movement depends on the 
activation of several transduction pathways such as 
EGFR, Ras and Rho GTPases, which trigger the actin-
mediated lateral membrane diffusion of HCV-CD81 
complexes[52-54]. It is reported that also TfR1 is 
engaged at a post-CD81 binding step in HCV entry 
and it is involved in the viral entry. Although the exact 
mechanism of action is unknown, the TfR1 inhibition 
decreases significantly the infection of HCV derived 
from cell culture (HCVcc) and HCV pseudoparticles 
(HCVpp), thus suggesting that it is involved in viral 
internalization. Interestingly, the cell-to-cell spread is 
less dependent on this molecule[55]. Similarly, OCLN 
is required for HCV entry and it acts after the GAGs 
and SR-BI post binding step and prior to endosomal 
acidification, thus suggesting that the tight junction 
region is the last to be encountered by the virion 
before cellular internalization[56].
The interaction of HCV-CD81 complexed with CLDN1 
induces clathrin-mediated endocytosis. Following 
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transported to the membranous web, rather than that 
the replication complexes take place in specific area 
of the ER enriched in cholesterol and sphingolipids. 
In fact, HCV is able to alter the lipid composition of 
membranes affecting the subcellular localization of 
the lipid kinase phosphatidylinositol-4-kinase Ⅲα 
(PI4KⅢα), which leads to a different distribution of 
its product phosphatidylinositol-4-phosphate (PI4P) 
from the Golgi compartment and plasma membrane 
to the cytoplasm[69,70]. HCV utilizes the redistribution of 
PI4P to alter the lipid composition of the membranous 
web, attracting sphingolipids and cholesterol through 
the recruitment of the PI4P-interacting lipid transfer 
proteins four-phosphate adaptor protein 2 (FAPP2), 
which is also a glycosphingolipid-binding protein, and 
oxysterol-binding protein (OSBP), respectively[71,72].
In addition to these structural and molecular 
alteration of membranes, HCV also induces de novo lipid 
and membrane biosynthesis modulating the expression 
of a number of genes involved in lipid metabolism. 
This is likely mediated by the transcriptional activity of 
the sterol regulatory element-binding protein (SREBP) 
pathway[73,74]. In this regards, it has been well described 
how HCV infection is able to alter the lipidomic profile of 
hepatocytes[75].
While the lipid metabolism involvement in HCV 
replication has been well demonstrated, the role 
of members of the lipoprotein machineries is far 
to be fully proved. It has been reported that LDLR 
is necessary for viral RNA replication. The use of a 
neutralizing antibody against LDLR after HCV RNA 
electroporation into Huh7 cells induced a decreased 
RNA production. The treatment with this antibody 
induced a changed in the cellular lipid profile, with an 
increase of CE level and a change in phospholipids 
[i.e., increased phosphatidylethanolamine (PE) and a 
lower phosphatidylcholine (PC) content]. Therefore, 
it is likely that LDLR is necessary to the virus to have 
the adequate amount and variety of lipids at the 
membranous web[42].
Although how LDLR contributes to HCV life cycle, 
in general, and to the viral entry step, in particular, 
is still controversial, its importance is undisputed. 
The role of this receptor in viral life cycle is further 
emphasized by the direct or indirect ability of HCV to 
modulate LDLR expression by both increasing its gene 
transcription and inhibiting its PCSK9-mediated protein 
degradation[44]. Interestingly, the HCV-mediated 
PCSK9 regulation has been reported to be different 
in patients infected with the genotype 3 compare to 
those with genotype 1, thus suggesting that HCV can 
affect lipoprotein metabolism in a genotype specific-
manner[76].
This hypothesis is indirectly supported by the 
observation that hepatoma cells transfected with core 
proteins of the different HCV genotypes displayed a 
genotype-specific intracellular TG accumulation[77]. This 
accumulation is probably caused by the virus-mediated 
inhibition of the microsomal triglyceride transfer 
protein (MTTP), a key enzyme in the apoB-containing 
lipoproteins assembly pathway[78]. It has been also 
found that the HCV genotype could also affect the 
circulating levels of apolipoproteins. In chronic patients 
the infection with genotype 1b was found to be an 
independent factor significantly associated with higher 
levels of apoA-Ⅱ and apoE, and lower levels of apoC-
Ⅱ and apoC-Ⅲ, while genotype 2 infection was 
associated only with lower levels of apoC-Ⅱ and apoC-
Ⅲ[79]. Moreover, the HCV genotypes influence the levels 
of LDL-cholesterol differently in patients with different 
IL28B polymorphisms, as well as the lipid-related 
genes expression in cultured cells[80]. These different 
effects on lipoproteins machinery, together with other 
pathogenic effects[81] could explain, at least partially, 
the HCV genotype-specific steatogenic effects.
Another connection between the lipoprotein meta-
bolism and the RNA replication step of the HCV life 
cycle was discovered in our laboratory. We found that 
apoA-I is involved in the replication step of HCV. In 
fact, the downregulation of apoA-I induces significant 
decrease of viral RNA levels in either replicon carrying 
cells and in the HCVcc infected cells[82]. 
Although apoA-I is the major structural protein of 
the HDL, we focused our attention on this exchangeable 
apolipoprotein because a decreased association of 
apoA-I to the circulating LDL of HCV infected patients 
was found by a proteomic analysis. This result sug-
gests that the function of apoA-I necessary for HCV 
replication could be linked to a its putative role in the 
biogenesis of apoB-containing lipoproteins rather than 
that of HDL. This is indirectly supported by the finding 
that the siRNA-mediated downregulation of apoA-I 
induces a significant reduction of HCV RNA only at later 
time point (day 4-6 post-silencing), when a decreased 
levels of apoB secretion was observed (unpublished 
results).
The apoA-I involvement in HCV replication were 
confirmed by others using different replicon system 
and siRNAs[83], thus lowering a possible off-targets 
effect, as recently underlined by a work on MOBKL1B 
by Rice’s group[84]. Interestingly, Saito’s laboratory 
found that one of the transcriptional effect of a histone 
deacetylase inhibitor treatment (SAHA) was the 
down-regulation of apoA-I and also the up-regulation 
of osteopontin (OPN), which are per se sufficient to 
induced the inhibition of HCV RNA replication[83].
Another apolipoprotein that has been described to 
influence HCV replication is apoH (also known as b2-
glycoprotein I), which was able to limit RNA replication 
using human liver slices as a HCV infection model[85]. 
Although, the authors have not proved a direct effect 
on HCV replication, treatment with apoH reduced HCV 
production while not affecting HCV entry[85]. A negative 
effect of apoH on the virus is also supported by the 
positive correlation between high plasma levels of apoH 
and viral clearance, both in spontaneous remission and 
in response to pegylated-interferon/ribavirin therapy 
in HCV patients[86]. Interestingly, patients carrying the 
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favorable IL28B rs12979860 CC SNP correlated with 
high plasma concentration of apoH, thus unveiling this 
apolipoprotein as a quantitative trait associated with 
IL28B[86].
Remarkably, apoH is part of the LDL[87] and it is 
known to influence the size and the lipid composition of 
LDL[88-90]. This further reinforces the idea that proteins 
affecting the generation of apoB-containing lipoproteins 
could have also an effect on HCV replication. However, 
since the inhibition of either apoB expression or MTTP 
function does not affect viral replication, this suggests 
that the distribution or the quality of lipids related to 
the lipoprotein machinery could influence HCV RNA 
production.
HCV VIRION PRODUCTION AND 
LIPOPROTEINS
The last step of the intracellular HCV life cycle is 
the formation of viral particle. The dynamic of virus 
assembly is challenging to track, suggesting that this 
process is either rare or rapid. However, it is now well 
recognized that the HCV virion biogenesis strictly 
relies mainly on lipid droplets (LD), the storage sites 
for neutral lipids in cells, and on the apoB-containing 
lipoprotein machinery[91-93].
HCV particles production is a coordinated and 
complex process regulated spatially and temporally 
by all viral proteins and host factors. Virion assembly 
is coordinated between the synthesis of new positive 
RNA strands, its encapsidation and the acquisition of 
envelop, likely via budding into the ER[94].
The RNA replication site and the formation of 
nucleocapsid has to be separated to avoid competition 
for the binding of viral RNA. This is obtained by the 
localization of the core protein on the surface of 
cytosolic LD, probably through the presence of two 
amphipathic helices and a palmitoylated conserved 
cysteine residue. The MAPK-regulated cytosolic 
phospholipase A2, group IVA (PLA2G4A) is important 
for the core recruitment at the LD and for the specific 
cleavages of lipids with arachidonic acid, which is 
essential for the production of highly infectious viral 
particles[95]. LD localization of core may be also 
enhanced by the diacylglycerol acyltransferase-1 
(DGAT-1)[96], an enzyme involved in LD morphogenesis 
that is also known to influence VLDL biogenesis[97]. 
The LD localization of core is an essential step. In 
fact, it regulates the recruitments of the other viral 
components and cellular factors, which regulate the 
transfer of both the newly replicated viral genomes 
from the membranous web and the HCV glycoproteins 
E1 and E2 from the ER, to the assembly site[94,98,99]. 
Although this step is not fully elucidated, it is likely 
regulated through protein-protein interactions between 
multiple viral proteins and a yet not fully unveil list of 
cellular proteins, as recently reviewed elsewhere[94,100].
Nascent virions, following maturation and acquisition 
of the typical low density, exit the cell via the secretory 
pathway. Although, the exact mechanisms are still 
poorly understood, it is now evident that assembly 
and secretion of HCV particles are associated with the 
VLDL/LDL pathway. There are different experimental 
evidences supporting this model. 
Notably, in humanized livers of transplanted 
SCID/Alb-uPA mice, HCV infection occurs only when 
the engraftment of human hepatocytes is sufficient to 
obtain a human-like lipoproteins profile while it is not 
correlated to the number of human hepatocytes[101].
In Huh7 cells, the isolation of membrane vesicles 
in which HCV replicates lead to the enrichment in 
different members of the apoB-containing lipoproteins 
such as apoB, apoE and MTTP[102]. Interestingly, the 
impairment of VLDL/LDL production through the 
downregulation of apoB or the inhibition of either MTTP, 
which stabilizes apoB by transferring lipids during its 
translation, or long chain acyl-coenzyme A synthetase 
3 (ACSL3), which mediates the phosphatidylcholine 
synthesis required for apoB secretion, lead to a 
decreased HCV particles production[102-105]. 
However, the direct requirement of apoB is contro-
versial. Other researchers did not find a dependency of 
HCV production on apoB but rather on the activity of 
apoE[106-108]. Moreover, it has been reported that MTTP 
inhibitors at low doses, which are effective for apoB 
secretion inhibition, are ineffective for HCV production, 
while at higher concentrations those inhibitors blocked 
apoE expression and secretion and, consequently, 
suppressed the generation of viral particles[106]. The 
ectopic expression of apoE, but not apoB or MTTP, was 
found necessary also for the production of infectious 
HCV trans-complemented particles in human non-
liver cells[108]. Moreover, apoE but not apoB was found 
necessary also for the cell-to-cell transmission of the 
virus. In fact, either the silencing of apoE in donor 
cells, but not in acceptor cells, inhibited the cell-to-cell 
viral spread[109].
A recent work of Matsuura’s lab smooth out 
the controversy. They showed that apoB and apoE 
redundantly participate in the formation of infectious 
HCV particles[110]. They generated Huh7 cells knock 
out for either or both apoB and apoE by zinc finger 
nucleases and found that the single knock out cells 
have a slightly reduction of HCV virions, while the 
apoB/apoE double knock out severely impaired 
the formation of infectious viral particles. More 
interestingly, they showed that the overexpression of 
different exchangeable apolipoproteins (i.e., apoA-I, 
apoA-Ⅱ, apoC-I, apoC-Ⅱ, apoC-Ⅲ, apoE but not 
apoH) in the double knock out Huh7 cells rescued the 
capability of producing viral particles[110]. 
These results were independently confirmed in 
complemented HCV virus production experiments 
using the non-permissive 293T/miR-122 cells 
transfected with HCV, in which the expression of cDNAs 
encoding for all members of the apoA and apoC family, 
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but not apoD, complemented HCV virus production, 
although at lower levels compared with apoE[111].
These results support the data obtained by different 
labs in which a requirement of other apolipoproteins 
for HCV production has been reported.
For instance, apoJ, a small heat shock protein 
that prevents unfolded secretory protein aggregation 
identified as a VLDL-associated protein[112], was 
found involved in efficient infectious HCV virion 
production[113]. ApoJ silencing decreased the HCV virion 
production, without affecting the HCV RNA replication, 
which could be restored upon reconstitution with a 
siRNA-resistant apoJ. Most likely, apoJ is involved 
at the step of virion assembly, since it was found 
to interact with core and NS5A, stabilizing the dual 
protein complex. Interestingly, immunofluorescence 
analysis showed that HCV infection induces a cellular 
redistribution of apoJ from Golgi to LD at the ER-Golgi 
membrane contact site[113].
Our lab found that the silencing of apoA-I induced 
a significant decrease in HCVcc production[82], although 
at lower levels respect of that of apoE (unpublished 
data). As described for other cellular components 
also the distribution of apoA-I was affected by HCV. 
We found that the apoA-I specific association to 
LDL was reduced in the circulating lipoproteins of 
HCV infected patients. Although it is known that 
the exchange of apolipoproteins among lipoprotein 
particles and interconversion of particles occurs in 
the plasma compartment, we found that the HCV-
induced decreased association of apoA-I with LDL 
has a cellular origin. The HCV-associated LDL-
specific reduction in apoA-I was also observed in the 
different HCV cellular models (i.e., HCVcc, genomic 
and subgenomic replicons). The results obtained 
with subgenomic replicon-carrying Huh7 cells, which 
recapitulate only the viral RNA replication step, 
indicate that the sole NS viral proteins are sufficient 
to impair the apoA-I/LDL association, thus reinforcing 
the hypothesis that VLDL/LDL biogenesis and viral 
replication could share common sites and bridging 
molecules. However, although apoA-I is known to 
be associated to the circulating VLDL and LDL[114,115], 
its role in the physiology of these lipoproteins is yet 
unknown. A possible role of apoA-I in the viral life cycle 
could be to drive HCV components in the right cellular 
compartments, and its binding activity to NS5A seems 
to support this hypothesis[116,117].
Moreover, as above mentioned, Fukuhara and 
colleagues found that different apolipoproteins are 
sufficient for HCV viral production in culture. More 
specifically, they found that the amphipathic α-helices 
present in the different apolipoproteins possess a 
redundant role in the assembly of HCV, through a 
direct interaction with the viral particles at the post-
envelopment step[110]. 
Interestingly, similar results were found for the 
replication step of HCV life cycle. The N-terminal 
amphipathic helix of NS5A, which motif is very 
similar to that of apolipoproteins, bound specifically 
to PI 4,5-bisphosphate [PI(4,5)P2], inducing a 
conformational change that stabilizes the interaction 
between NS5A and TBC1D20, which is required for 
HCV replication[118].
Since phosphoinositides bind and regulate localization 
of proteins via a variety of structural motifs, these 
results support the hypothesis that the requirement 
of the different apolipoproteins is related to the 
proper cellular localisation of viral components, which 
is necessary for the exploitation of lipid, in general, 
and of the lipoprotein metabolism, in particular. In 
other words, HCV may modulate the production of 
lipoproteins in the host cells to make this pathway 
more appropriate for viral maturation.
This point of view is supported by the observation 
that there is no correlation between the ability to 
generate VLDL and the production of LVP. In fact, the 
VLDL-producing HepG2 cells generated LVP similar, 
for both density and apolipoproteins content, to those 
generated by the VLDL-deficient Huh7.5 cells[119]. 
However, it is important to note that dissimilarities 
exist in the molecular composition of LVP found in 
HCV patients or generated in culture; for instance 
serum LVP could be immunoprecipitated by anti-apoB 
antibodies while the interaction with HCVcc is less 
efficient[29]. 
These discrepancies should be kept in mind 
because may have major implications for our under-
standing of HCV assembly and secretion. In fact, the 
exact model for the LVP composition is not yet defined. 
It has been proposed either a single-particle model, 
in which HCV exists as a hybrid particle fused to a 
VLDL/LDL, or as a two-particles structure, in which the 
virion is surrounded by lipoproteins (Figure 1).
CONCLUSION
HCV interacts with and hijacks host cell machineries 
and pathways to generate a chronic and productive 
infection. It is now well established that HCV has an 
intimate relationship with the host lipid metabolism, 
which has a role in all the steps of the viral infectious 
cycle. In particular, HCV modulates the production of 
lipoproteins in the host cells to make it more effective 
for viral production, propagation and persistence. 
The virus circulates in the bloodstream as a highly 
lipidated LVP, although it is not yet known whether 
fused with or surrounded by lipoproteins (Figure 1). 
HCV utilizes the lipoproteins pathways for cell entry, 
virus assembly and, possibly also for RNA replication. 
Moreover, it is becoming recognized that its strict 
resemblance with VLDL/LDL may contribute to the 
viral immune evasion strategies, such as masking 
viral epitopes or escaping from anti-HCV neutralizing 
antibodies directed against either viral proteins or the 
entry factors involved in lipoproteins pathways (i.e., 
CD81 and SR-BI as reviewed by Vercauteren and 
coauthors[120]).
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What has not been investigated yet is the possible 
involvement of lipid/lipoprotein metabolism in the 
dysregulation of the immune response mediated by 
HCV, as recently reported for the hepatitis B virus[121]. 
Recent evidences showing that LVP affect dendritic 
cells maturation[122], ApoE3 blocks the antiviral effect 
of ficolin-2[123] and the VLDL and LDL of chronic 
infected patients induce an altered intracellular 
lipid production[124] suggest that the HCV-induced 
modification of lipoprotein metabolism could be 
involved in the regulation of the immune response.
Overall, decoding the multiple interactions that 
HCV establishes with the lipoproteins pathways is 
mandatory to obtain a deeper knowledge of HCV 
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Figure 1  hepatitis C virus life cycle. Following the initial binding of hepatitis C virus (HCV) to glycosaminoglycans present on heparan sulfate proteoglycans 
(HSPGs), to low-density lipoprotein receptor (LDLR), to scavenger receptor class B type 1 (SR-BI) and to CD81, the viral particles utilize different proteins, such 
as epidermal growth factor receptor (EGFR), Ras, Rho ephrin receptor A2 (EphA2), transferrin receptor 1 (TfR1), cholesterol transporter Niemann-Pick C1-like 1 
(NPC1L1), claudin-1 (CLDN1) and occludin (OCLN), for entering into the cell by clathrin-mediated endocytosis. After the pH-dependent fusion between viral and target 
membranes, HCV RNA is released into the cytosol and translated at the rough ER, giving rise to a polyprotein that is then cleaved into mature viral proteins. Viral 
proteins together with host cell factors, induce the formation of the membranous web (MW), composed by vesicles as well as cytosolic lipid droplets (cLD) where the 
RNA replication occurs. Assembly of HCV particles probably starts in close proximity to the ER and lipid droplets. The viral envelope is acquired by budding into the 
ER at sites of lipoprotein synthesis. HCV particles are thought to be released via the constitutive secretory pathway in association with components of lipoproteins in 
order to produce a mature form of lipoviroparticles (LVP). This lipidation might occur either during budding (hybrid particle model; Ⅰ) or during egress via interaction 
between the virion and lipoproteins (dual-particle model; Ⅱ).
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biology and pathogenesis, a step necessary to 
understand and to manage the reversibility of liver 
damages upon DAAs-mediated viral clearance.
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